CA2372960A1 - Compositions et procedes immunogenes anti-vih - Google Patents
Compositions et procedes immunogenes anti-vih Download PDFInfo
- Publication number
- CA2372960A1 CA2372960A1 CA002372960A CA2372960A CA2372960A1 CA 2372960 A1 CA2372960 A1 CA 2372960A1 CA 002372960 A CA002372960 A CA 002372960A CA 2372960 A CA2372960 A CA 2372960A CA 2372960 A1 CA2372960 A1 CA 2372960A1
- Authority
- CA
- Canada
- Prior art keywords
- hiv
- immunogenic compositions
- antigen
- mammal
- hiv antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 241000124008 Mammalia Species 0.000 abstract 3
- 102000001902 CC Chemokines Human genes 0.000 abstract 2
- 108010040471 CC Chemokines Proteins 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 2
- 230000003308 immunostimulating effect Effects 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 101710205625 Capsid protein p24 Proteins 0.000 abstract 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 abstract 1
- 101710091045 Envelope protein Proteins 0.000 abstract 1
- 101710177166 Phosphoprotein Proteins 0.000 abstract 1
- 101710188315 Protein X Proteins 0.000 abstract 1
- 101710149279 Small delta antigen Proteins 0.000 abstract 1
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13276299P | 1999-05-06 | 1999-05-06 | |
| US60/132,762 | 1999-05-06 | ||
| US15066799P | 1999-08-25 | 1999-08-25 | |
| US60/150,667 | 1999-08-25 | ||
| PCT/US2000/012495 WO2000067787A2 (fr) | 1999-05-06 | 2000-05-05 | Compositions et procedes immunogenes anti-vih |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2372960A1 true CA2372960A1 (fr) | 2000-11-16 |
| CA2372960C CA2372960C (fr) | 2006-03-28 |
Family
ID=26830710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002372960A Expired - Fee Related CA2372960C (fr) | 1999-05-06 | 2000-05-05 | Compositions et procedes immunogenes anti-vih |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1176978A2 (fr) |
| AP (1) | AP1891A (fr) |
| AU (1) | AU4992900A (fr) |
| BR (1) | BR0010323A (fr) |
| CA (1) | CA2372960C (fr) |
| CR (1) | CR6491A (fr) |
| OA (1) | OA11937A (fr) |
| WO (1) | WO2000067787A2 (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| ES2628744T3 (es) | 1998-05-22 | 2017-08-03 | Ottawa Hospital Research Institute | Métodos y productos para inducir inmunidad en mucosas |
| JP2003523721A (ja) | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
| US7776343B1 (en) | 1999-02-17 | 2010-08-17 | Csl Limited | Immunogenic complexes and methods relating thereto |
| ES2250151T3 (es) * | 1999-06-29 | 2006-04-16 | Glaxosmithkline Biologicals S.A. | Uso de cpg como adyuvante de vacuna contra vih. |
| JP4188687B2 (ja) | 2000-12-27 | 2008-11-26 | ダイナバックス テクノロジーズ コーポレイション | 免疫変調ポリヌクレオチド及びその使用法 |
| CA2435568A1 (fr) * | 2001-01-26 | 2002-08-01 | The Immune Response Corporation | Procede de traitement d'un individu infecte par le vih en associant l'immunisation a une interruption structuree du traitement antiretroviral |
| US8114418B2 (en) | 2001-06-21 | 2012-02-14 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—IV |
| CA2634992C (fr) | 2001-07-05 | 2012-10-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations |
| NZ552377A (en) | 2001-08-17 | 2008-08-29 | Coley Pharm Gmbh | Combination motif immune stimulatory oligonucleotides with improved activity |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| CA2388049A1 (fr) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Oligonucleotides immunostimulateurs et utilisations connexes |
| US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| CA2494508A1 (fr) * | 2002-07-03 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Compositions d'acide nucleique destinees a stimuler les reponses immunitaires |
| US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| ES2381224T3 (es) | 2002-10-29 | 2012-05-24 | Coley Pharmaceutical Group, Inc. | Uso de oligonucleótidos CPG en el tratamiento de infección por el virus de la hepatitis C |
| JP2006512927A (ja) | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ，インコーポレイテッド | ５’ｃｐｇ核酸およびその使用方法 |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| ES2381309T3 (es) | 2002-12-23 | 2012-05-25 | Dynavax Technologies Corporation | Secuencia de oligonucleótidos inmunoestimuladores y métodos para usar los mismos |
| WO2005021726A2 (fr) * | 2003-08-28 | 2005-03-10 | The Immune Response Corporation | Compositions immunogenes contre le vih et methodes correspondantes |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| MX2009003398A (es) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
| WO2010051820A1 (fr) * | 2008-11-10 | 2010-05-14 | Aarhus Universitet | Vaccination contre multiplexée par la cytokine |
| JP6059220B2 (ja) | 2011-07-06 | 2017-01-18 | ノバルティス アーゲー | 核酸を含む水中油型エマルジョン |
| CA2840965C (fr) | 2011-07-06 | 2021-03-02 | Novartis Ag | Emulsions huile dans eau cationiques |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5087758B2 (ja) * | 1997-03-10 | 2012-12-05 | オタワ ホスピタル リサーチ インスティチュート | アジュバントとして非メチル化ＣｐＧジヌクレオチドを含む核酸の使用 |
| US6225292B1 (en) * | 1997-06-06 | 2001-05-01 | The Regents Of The University Of California | Inhibitors of DNA immunostimulatory sequence activity |
-
2000
- 2000-05-05 EP EP00932163A patent/EP1176978A2/fr not_active Withdrawn
- 2000-05-05 OA OA1200100291A patent/OA11937A/en unknown
- 2000-05-05 BR BR0010323-3A patent/BR0010323A/pt not_active IP Right Cessation
- 2000-05-05 CA CA002372960A patent/CA2372960C/fr not_active Expired - Fee Related
- 2000-05-05 AU AU49929/00A patent/AU4992900A/en not_active Abandoned
- 2000-05-05 AP APAP/P/2001/002300A patent/AP1891A/en active
- 2000-05-05 WO PCT/US2000/012495 patent/WO2000067787A2/fr active Application Filing
-
2001
- 2001-10-25 CR CR6491A patent/CR6491A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2372960C (fr) | 2006-03-28 |
| WO2000067787A3 (fr) | 2001-04-26 |
| EP1176978A2 (fr) | 2002-02-06 |
| CR6491A (es) | 2005-05-31 |
| BR0010323A (pt) | 2002-01-08 |
| AP2001002300A0 (en) | 2001-12-31 |
| WO2000067787A2 (fr) | 2000-11-16 |
| OA11937A (en) | 2006-04-12 |
| AU4992900A (en) | 2000-11-21 |
| AP1891A (en) | 2008-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2372960A1 (fr) | Compositions et procedes immunogenes anti-vih | |
| DE59913046D1 (de) | Influenzavirus-impfstoffzusammensetzung | |
| NZ583028A (en) | Nucleic acids and proteins from streptococcus groups A & B | |
| HK1044484A1 (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide. | |
| EP2039699A3 (fr) | Procédés d'extraction pour purifier le sucralose | |
| EP2341062A3 (fr) | Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques | |
| KR970705403A (ko) | 비독성 경구용 어쥬번트로써 효과적인 장독소 돌연변이체(mutant enterotoxin effective as a non-toxic oral adjuvant) | |
| EP1754703A3 (fr) | Dérives n-hétérocycliques utiles en tant que inhibiteurs du nos | |
| HUP0302086A2 (hu) | Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására | |
| DE60210456D1 (de) | Solubisierung von kapseln polysacchariden | |
| WO2001044286A3 (fr) | Proteine a cinq helices | |
| WO2001093902A3 (fr) | Molecules hybrides arn/adn immunostimulatrices | |
| EP1144998A3 (fr) | Sequences genomiques de neisseria et procedes d'utilisation | |
| WO2002060926A3 (fr) | Inhibiteurs du virus de l'hepatite c | |
| EP1568373A3 (fr) | Induction de reponses immunes cellulaires a HER2/neu a l'aide de compositions renfermant des peptides et des acides nucleiques | |
| HUP0101323A1 (hu) | Vakcinakészítmények | |
| MY136081A (en) | Modified hiv - 1gag p17 peptide and immunogenic composition | |
| HK1042425A1 (en) | Enhancement of bactericidal activity of neisseria s. antigens with oligonucleotides containing cg motif | |
| WO2001000232A3 (fr) | Vaccin | |
| GB2428042A (en) | P gingivalis vaccine | |
| AU5537096A (en) | Isolated frpb nucleic acid molecule and vaccine | |
| WO2005013918A3 (fr) | Compositions, methodes et kits de vaccins a base de sous-unite de poxvirus | |
| WO2005021726A3 (fr) | Compositions immunogenes contre le vih et methodes correspondantes | |
| AU6078399A (en) | Ligand presenting assembly (lpa), method of preparation and uses thereof | |
| WO2003030935A3 (fr) | Vaccin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |